Our work shows that hypoxia enhances IL-6-mediated CD40 expression in tumor Mφs, implicating that cancer therapy by modulation of tumor metabolism or normalization of blood vessels to relieve tumor hypoxia may need additional CD40 agonist treatment to stimulate anti-tumor immunity. This evidence concerns the gene IL6 and neoplasm.